2006
Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab
Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC. Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab. Transplantation Proceedings 2006, 38: 1307-1313. PMID: 16797289, DOI: 10.1016/j.transproceed.2006.02.116.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionSteroid avoidance immunosuppressionKidney transplant recipientsAntithymocyte globulinAcute rejectionTransplant recipientsMonths posttransplantationAcute rejection-free survivalType 1 diabetes mellitusRabbit antithymocyte globulinRejection-free survivalAcute rejection riskInduction therapyMaintenance immunosuppressionProtocol biopsiesRapid discontinuationMost patientsDiabetes mellitusMedian timeLower incidenceRejection riskBasiliximabImmunosuppressionDay 4Overall risk
2004
Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy
Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology 2004, 127: s261-s267. PMID: 15508092, DOI: 10.1053/j.gastro.2004.09.040.Peer-Reviewed Original ResearchConceptsNumber of patientsHepatocellular cancerHCC patientsWaiting listLiver transplantationDeceased donorsExcellent long-term survivalPost-MELD eraAdvanced stage diseaseLiver transplant candidatesLong-term survivalHigh mortality rateProgression of HCCHCC recipientsPosttransplant survivalStage diseaseTransplant candidatesUnited NetworkDonor organsLower incidenceMortality ratePatientsAdvanced stageEarly assessmentTransplantation